Breaking AI & Tech News Analyzed

World Health Organization Director-General Tedros Adhanom Ghebreyesu confirmed on 31 May 2026 that five individuals infected with the rare Bundibugyo Ebola strain have recovered, including four who will be discharged today and one who left the hospital on Friday. The announcement came as the WHO opened a new treatment centre in Bunia, Ituri province, DRC.First Recoveries Confirmed in Bundibugyo Ebola OutbreakThe recoveries represent the first documented successes against a strain that has no approved vaccine or specific therapy. Doctors Without Borders (MSF) had described the situation as “deeply alarming” due to rapid case growth and diagnostic challenges.Outbreak Statistics Highlight Ongoing ThreatSuspected cases: ~1,000Suspected deaths: >220Current confirmed cases in DRC: rising rapidly across Ituri provinceCross‑border impact: Uganda reports 1 death and 9 casesThe Bundibugyo strain historically carries a case‑fatality rate of up to 50%, intensifying concerns about containment.Health System Strain and Regional Risks IntensifyLimited testing capacity and the absence of approved medical countermeasures have stretched local health infrastructure. MSF warned that the response has not yet caught up with the epidemic’s speed, and the outbreak’s proximity to the Ugandan border raises the risk of cross‑border transmission.Outlook: Vaccine Development and Containment ProspectsWhile the recoveries provide a morale boost, experts stress that sustainable control will depend on accelerated vaccine research, expanded diagnostic capacity, and coordinated regional surveillance. The WHO’s new treatment centre aims to improve patient outcomes, but long‑term containment will require international funding and rapid deployment of experimental therapeutics.

The Pavlovian Paradox: Mosquitoes Learn to Associate DEET with FoodFor decades, the efficacy of DEET (N,N-diethyl-meta-toluamide) has been attributed solely to its chemical properties, which are believed to either repel insects or block their ability to detect humans. However, a new study led by Professor Claudio Lazzari from the University of Tours suggests a more complex behavioral interaction. The research indicates that mosquitoes can learn to associate the scent of DEET with the presence of a blood meal, effectively turning a repellent into a lure through a process similar to Pavlovian conditioning.Experimental Evidence: From Repellent to LureThe study, published in the Journal of Experimental Biology, involved trapping mosquitoes and presenting them with warm blood that was just out of reach. The insects were simultaneously exposed to DEET. The results demonstrated a significant shift in behavior:Trained Group: 60% of mosquitoes that fed while exposed to DEET subsequently attempted to bite when exposed to the repellent alone.Control Groups: Significantly lower percentages were observed in untrained insects (17%) and those with prior exposure to DEET alone (13%).In a real-world test, nearly 60% of the trained mosquitoes attempted to bite a researcher's DEET-treated hand, whereas untrained mosquitoes universally targeted the untreated hand.Redefining Insect Control StrategiesThis discovery represents a significant shift in our understanding of how repellents work. It suggests that the reaction to DEET is not merely a chemical aversion but can be modified by experience. Experts, including Dr. Nina Stanczyk of ETH Zürich, emphasize that while the learning ability of mosquitoes is impressive, the implications for public health are nuanced. The study highlights that repellents may function differently depending on the context of the mosquito's previous interactions with humans.Future Outlook for TravelersDespite the alarming findings, experts urge travelers not to abandon DEET. The consensus is that this phenomenon occurs under specific laboratory conditions and is unlikely to happen frequently in the wild due to the variability of repellents encountered during different blood meals. The key takeaway for the future is the importance of consistent application. As noted by the researchers, the risk of association is highest when the repellent starts to wear off, reinforcing the need for regular reapplication to maintain protection.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

The Concept of 'Mind Children' A few months ago, an AI researcher from Europe attended a dinner party in Silicon Valley. During one of the many courses, the host addressed his guests, all of whom worked in AI. The researcher paraphrased his message like this: “Isn’t it amazing that we are the last generation of humans who will need to think about procreating biologically? We were lucky enough to be born at a time where we can simply upload our consciousnesses instead.” The Book That Sparked the Conversation The book in question was Hans Moravec’s Mind Children: The Future of Robot and Human Intelligence, which was first published in 1988, and which at the time, according to economist and futurist Robin Hanson of George Mason University, caused a big splash in a small pond – the community of robotics and machine-learning experts to which Moravec belonged. The Data Analysis Moravec’s book is more philosophical treatise than technological manual, but the central idea is that cultural evolution has long since taken over from biological evolution as the most powerful force shaping humanity. The logical extrapolation of this is that the information that encodes our future selves would soon be packed into hardware and software rather than DNA. The Impact Analysis Angela Aristidou, who studies the real-life deployment of AI at University College London, is not surprised that Moravec’s book is enjoying a revival. She says that what in 1988 might have read like science fiction – and still might to most of us – looks eminently realisable to those in the know. The Prediction Hanson shares his conviction that the revolution is inevitable, as soon as AI attains something experts agree to call human-level intelligence. “We are going to generate an explosion of things like us in the future, who will be different from us in many ways,” Hanson says. “To the extent that they have minds somewhat like ours, they are our mind children.”

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The Shift from Exit Point to DestinationFor decades, the museum gift shop was a secondary consideration—a place to buy a postcard before leaving. However, a significant strategic pivot is underway. Museums are now treating their retail spaces as primary destinations, curating lifestyle collections that rival high-street fashion stores. This shift aims to boost revenue and deepen the connection between the institution and the public, effectively turning the 'exit through the gift shop' into an 'entry point' for shopping.Curated Lifestyle MerchandisingThe core of this transformation is the move away from literal reproductions of artwork toward thematic, lifestyle products. Curators are developing collections that interpret exhibitions through fashion and homeware rather than just posters.National Portrait Gallery (NPG): For the upcoming Marilyn Monroe exhibition, the shop features cat-eye sunglasses, a signature red lipstick, and baseball caps with Monroe’s scrawl.Tate Modern: To mark Tracey Emin’s exhibition, the shop offers cat feeding bowls and cat-shaped hair clips.V&A; Dundee: For the catwalk exhibition, the merch includes bottles of hairspray and gold scissors.Design Museum: The Wes Anderson archival exhibition features Earl Grey teabags in pink patisserie boxes and 'Asteroid City' alien logo T-shirts.The Financial Power of Pop CultureThis merchandising strategy is proving to be a lucrative revenue stream. Merchandise is no longer a 'nice add-on' but a primary expectation for visitors. The V&A; reported that merchandise from its Taylor Swift exhibition generated £1.1m in just seven weeks, a record high for the institution.The product range is diverse, catering to different budgets. Items range from £3 magnets to high-end pieces like a £380 'Rave culture' vase, ensuring accessibility while offering luxury items for collectors.Cultural Capital and the 'Walking Gallery'Analysts suggest this trend is driven by the concept of 'cultural capital.' Bridget Dalton describes this as a 'triple whammy' where consumers buy products that represent their interests and support a national institution. It allows individuals to express their intellectualism and cultural engagement through fashion.This approach resonates strongly with Gen Z, who document their museum visits and purchases on TikTok as 'museum hauls.' For this demographic, seeing these products on social media often drives ticket sales, creating a feedback loop between social media trends and physical attendance.The Future of Institutional RetailAs museums continue to blur the lines between cultural institutions and retailers, we can expect to see more collaborations with independent makers and up-and-coming designers. The goal is to create a 'grown-up' form of fandom where visitors can wear their interests, effectively becoming a 'walking gallery' that demonstrates their knowledge and cultural engagement.

The Rise of Nigeria's Digital Herbal Marketplace In Abuja, Nigeria, Oke Bola thought a fertility supplement she found online might help her conceive. Instead, within days of taking it, she struggled to breathe. Her experience reflects a growing online trade in unverified herbal remedies promoted across social media platforms. Bola, who is in her early 40s and has never had children, bought the supplement earlier this year and increased the recommended dosage, hoping for quicker results after hearing about it from friends and family. "I recognised the symptoms of asthma; the wheezing sound at night was familiar," she told Al Jazeera. "When I checked online, I realised it could be from the herbal medication." Her experience is not isolated. Across Nigeria, doctors and pharmacists report a surge in social media-driven self-medication, particularly involving unverified herbal products. This trend is worsening health outcomes, delaying treatment, and adding pressure to an already strained healthcare system serving about 230 million people. Nigeria's young, hyperconnected population increasingly uses digital platforms for health information and advice. But that access has also created what Dr Isaac Kolawole and Dr Fidelis describe as an "algorithmic apothecary" – an unregulated online marketplace where influencers and anonymous sellers promote remedies directly to consumers with little or no scientific backing. Health Impacts of Unverified Herbal Remedies Within this ecosystem, herbal remedies, long part of Nigeria's medical and cultural landscape, are increasingly repackaged as miracle cures, sometimes with dangerous consequences. Doctors report more patients arriving at hospitals only when their conditions have significantly worsened, often after prolonged use of unverified treatments. A consultant nephrologist at the University College Hospital in Ibadan, Dr Yemi Raji, said herbal medicine continues to play a role in kidney disease cases in Nigeria. "When you take herbal medication, you are taking both the good and the bad," he said. "Patients often arrive late, when treatment is more difficult and expensive." Dialysis alone can cost between 50,000 and 100,000 naira ($36-72) per session, several times a week. Studies link herbal use to kidney and liver disease cases across Africa, including findings that about 46 percent of liver disease admissions in one Nigerian hospital involved herbs or roots. A 2022 study found that 76.65 percent of participants had used herbal medicine, with more than a third combining herbal and conventional treatments while 82.44 percent did not inform their doctors. The Algorithmic Amplification Effect On a smartphone screen, relief is just a click away: fertility tonics, eye drops promising restored vision, syrups claiming to "flush out" disease. The advertisements are polished, persuasive and constant, woven into TikTok, Facebook, Instagram and X feeds. "The platforms themselves amplify this effect," said Dr Egemba Chinonso Fidelis, a public health advocate known online as Aproko Doctor. "Their algorithms reward engaging content and push it to wider audiences." Even users who try to avoid such content often encounter it repeatedly, shaped by emotional storytelling, music and urgency-driven messaging. A 2025 Nigeria-based study on Jinja Herbal Mixture found it appeared safe for short-term use within tested dosage ranges, but researchers recorded biochemical changes at higher doses, including altered creatinine and sodium levels in test subjects, signs of possible kidney and liver stress. The study called for further research into long-term effects and interactions with conventional medicines. Regulatory Challenges in the Digital Age The National Agency for Food and Drug Administration and Control (NAFDAC) says it is working to track unregistered manufacturers, but enforcement remains difficult, especially online. "With the sheer volume of products online, enforcement has limited reach," said Isaac Kolawole, the southwest zonal director of NAFDAC. Many sellers use fake or incomplete addresses, making them difficult to trace. NAFDAC requires strict registration, testing and approval before herbal products can be sold or advertised, but regulation has not kept pace with online commerce. Fidelis argued that stronger regulation alone is not enough. "If there are no consequences for lying about healthcare online, people will keep doing it," he said. He noted that scammers have even used AI-generated versions of his image to promote fake products. "Real medicine does not promise to cure everything, and it does not rely on countdowns," he added. "Scammers do." Path Forward for Safer Digital Health As Nigeria's digital economy expands, the intersection of technology and healthcare will only grow more complex. Fidelis stressed that access to affordable healthcare must improve, public trust must be rebuilt, and digital platforms must take responsibility for the health content they amplify. Pharmacist Akinade Akinlolu noted that while conditions like diabetes and hypertension can be managed, online claims often suggest cures. "Economic pressure is also pushing people towards cheaper or 'miracle' alternatives," he added. "Without stronger safeguards," Fidelis warned, "the algorithmic apothecary will continue to grow and put more people at risk." The challenge for Nigeria's healthcare system is to harness the power of digital platforms while ensuring they promote evidence-based care rather than potentially harmful alternatives.

Why the EU’s Northern Strategy Is Under ScrutinyThe Guardian column points out that the EU’s ability to act as a security anchor in the increasingly contested Arctic is being tested by external threats and internal quirks. As the United States under Donald Trump flexes its Arctic ambitions, northern nations are weighing whether deeper EU integration can offer a more reliable shield.EU’s Institutional Quirks and the Brussels‑Strasbourg CommuteCommissioners are forced to travel 280 miles between Brussels and Strasbourg in electric vehicles supplied under the EU’s Green Deal, yet the commission president, Ursula von der Leyen, still uses a petrol‑engine car. The dual‑city parliamentary schedule, mandated by treaty, requires twelve sessions a year, prompting criticism of wasteful bureaucracy.Financial Toll of Dual‑City SessionsTaxpayer cost runs into tens of millions of euros annually for the Brussels‑Strasbourg trips.In 2023 a train carrying MEPs was mistakenly diverted to Disneyland, underscoring logistical mishaps.These expenses are highlighted as emblematic of a broader “gravy train” perception that fuels scepticism about EU efficiency.Rising Pro‑EU Sentiment in Iceland, Norway and GreenlandIceland will hold a referendum in August 2026 on resuming accession talks after signing a security‑defence partnership in March.Norway’s main conservative opposition now advocates joining the bloc.Faroe Islanders are reconsidering independence from Denmark amid US pressure on Greenland.Trump’s “ice‑boat diplomacy” has pushed Greenlanders closer to Denmark and the EU.These developments reflect a shared fear of external aggression from the US, Russia and China, prompting northern populations to view EU membership as a security guarantor.What the Next Five Years Could Hold for EU Enlargement and Arctic SecurityIf the EU can reform its sluggish institutions and present a credible defence posture—potentially a “European army”—it may capture the loyalty of the north. Failure to act could see the region drift further into US‑led security arrangements or remain vulnerable to hybrid threats highlighted by recent Russian jamming attacks on UK defence assets.

On 31 May 2026, the Euphrates River overflowed in eastern Syria, flooding towns along its banks and triggering urgent rescue missions by Syrian civil defence, the United Nations and the Red Crescent. Rapid Response to the Euphrates Overflow in Eastern Syria Rescue teams deployed over 200 boats and dozens of trucks to reach stranded families. Emergency shelters set up in Deir ez‑Zor and surrounding villages. International NGOs coordinated with local authorities to prioritize vulnerable groups, including children and the elderly. Preliminary Numbers on Evacuations and Aid Distribution Authorities report that approximately 12,000 people have been evacuated so far. Food parcels and clean water have been delivered to more than 8,000 individuals. Medical teams are treating over 300 injuries related to flood exposure. Humanitarian and Regional Implications of the Flood The flooding threatens agricultural lands that supply a significant portion of the region’s wheat and vegetable output. Displacement adds pressure to already strained refugee camps and internally displaced‑person (IDP) settlements. Cross‑border trade routes along the Euphrates face temporary closures, potentially affecting supply chains to neighboring Iraq. Outlook for Recovery and Future Flood Mitigation Local authorities plan to reinforce riverbanks and improve early‑warning systems before the next rainy season. UN agencies are mobilising additional funds to support long‑term reconstruction of homes and infrastructure. Continued monitoring will determine whether further evacuations are required as water levels recede.